MCE products for research use only. We do not sell to patients.

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat

MCE China：Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat

Brand：MedChemExpress (MCE)

Cat. No.HY-P1240

CAS：149635-73-4

Synonyms：MOG (35-55)

Purity：99.97%

Storage：Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 year *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Shipping：Room temperature in continental US; may vary elsewhere.

Description：Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat has encephalitogenic activity and induces T?cell proliferative. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat induces Th1 cytokine response as well as relatively high levels of IgG antibodies. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination.

In Vitro：Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55); 0-50 μg/mL; 72 h; lymph nodes cells) induces T?cell proliferative and secretes Th1 cytokines including IFN-γ, TNF-α, IL-10, IL-4 and IL-5. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat increases the level of IgG[1].

In Vivo：Myelin oligodendrocyte glycoprotein (MOG) peptide 35-55 is one of the targets of self-reactive T cell responses, leading to acute and later chronic autoimmune processes. MOG 35-55 is capable of inducing experimental autoimmune encephalomyelitis (EAE) in B6 mice[1]. .f12{ font-size: 12px; } .fwb{ font-weight: bold; } .lh22{ line-height: 22px;; } .lh23 { line-height: 23px; } .pl13{ padding-left: 13px;; } .part { margin-top: 18px; } .mold-first-tit { width: 100%; height: 44px; line-height: 44px; background: #F9F7FB; border-bottom: 1px solid #EBE4F6; padding-left: 16px; box-sizing: border-box; margin-bottom: 17px; } .mold-second-tit:before { content:""; width: 6px; height: 6px; display: inline-block; border-radius: 50%; background: rgba(255,102,0,0.4); margin-right: 12px; position: relative; top: -3px; } .lft-border { border-left: 1px dotted #EBE4F6; padding-right: 12px; margin-left: 3px; box-sizing: border-box; padding-bottom: 12px; } /* .part .dec:last-child { border-bottom: 0; } */ .dec { margin: 10px 15px 0; padding-bottom: 10px; border-bottom: 1px dashed #EBE4F6; } .btm-border { border-left: 1px dashed #EBE4F6; } .text-bg { margin-top: 10px; background: #FFFBF1; padding: 14px; border-bottom: 0; position: relative; } .text-note-bg { margin-top: 10px; background: #FFFDF7; padding: 12px; border-bottom: 0; position: relative; } .text-note { width: 51px; height: 20px; line-height: 20px; background: #FFE2AA; text-align: center; border-radius: 0 0 8px 0; position: absolute; top: 0; left: 0; } .text-note-dec { margin-top: 15px;; } Induction of experimental autoimmune encephalomyelitis (EAE) model[3] Background Myelin Oligodendrocyte Glycoprotein Peptide (35-55) CAN trigger an immune response against the CNS, and induces inflammation and destruction of myelin or antigen-bearing structures that causes neurological abnormalities. Specific Mmodeling Methods Mice: C57BL/6 background mice • 2–4 months old • male and femaleAdministration: On day 0: 3 mg/mL peptide plus CFA (4 mg/mL) • Mix thoroughly 1: 1 peptide and CFA solutions • s.c. • 100 μL for each hind flank; • On day 0 and day 2: 2.5 μg/mL of Bordetella pertussis toxin • i.p. • 200 μL Note 1. Once peptide and CFA emulsion is formed, it can be stored at 4 °C for a few hours or used immediately.2. Symptoms appear approximately 10–15 days after immunization.3. When mice have clinical symptoms of EAE, hydrated food is placed on the cage floor to facilitate access to these mice.4. Record parameters every other day at the beginning, and daily from 7th postimmunization day. Body weight decreases usually precedes EAE clinical signs and is a very objective and valuable measure. Modeling Indicators Evaluate changes in body weight and clinical scoring: body weight loss, loss of tail tonus, paralyzed tail, hind limb paraparesis, hind limb paralysis, front leg paralysis, tetraplegia, moribund, etc.prototypical histopathological changes: Luxol fast blue staining of spinal cord for myelin evaluation shows infiltrates and demyelination in EAE animals. Correlated Product(s): Complete Freund's adjuvant (CFA) (HY-153808) Opposite Product(s): /

Hot selling product：BIM-23056  | Glycitin  | Lipoprotein lipase  | Wu-5  | α-Arbutin  | Ras Antibody  | Nagilactone B  | H3K4(Me3) (1-20)  | Phosphoglycerate kinase  | CREBtide

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Rich C, et, al. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol. 2004 May;34(5):1251-61.  [Content Brief]

[2]. Slavin A, et, al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity. 1998;28(2):109-20.  [Content Brief]

[3]. Giralt M, et, al. Active Induction of Experimental Autoimmune Encephalomyelitis (EAE) with MOG35-55 in the Mouse. Methods Mol Biol. 2018;1791:227-232.  [Content Brief]